Lubiprostone for chronic constipation in adults.
Lubiprostone (Amitiza-Sucampo Pharma Europe), a chloride-channel activator is licensed for the treatment of chronic idiopathic constipation in adults. It received a marketing authorisation in the UK in September 2012. In this article, we consider the evidence for lubiprostone in the management of constipation and how the treatment fits with current management strategies for constipation.
D000328:Adult; D000527:Alprostadil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D065101:Chloride Channel Agonists / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002908:Chronic Disease; D003248:Constipation / Q000188:drug therapy*; D016527:Drug Costs; D006801:Humans; D000068238:Lubiprostone
D065101:Chloride Channel Agonists; D000068238:Lubiprostone; D000527:Alprostadil